“Treatment of Diffuse Systemic Sclerosis with AIMSPRO” Publication Features in October Edition of Annals of the Rheumatic Diseases Journal
EASTBOURNE, England, October 7, 2013 /PRNewswire/ –
A detailed publication entitled “Treatment of diffuse systemic sclerosis with
hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial”
written and submitted by Professor Christopher Denton, Doctor Niamh Quillinan, Professor
Syed Haq, Doctor Deirdre McIntosh and Jeffrey Vernes has been published in the globally
renowned Annals of the Rheumatic Diseases journal, the EULAR journal.
The results from the trial showed statistical and near statistical significant changes
in key clinical outcomes, such as a reduction in the Modified Rodnan Skin Score, mRSS
(p=0.041); a responder rate of 50% (AIMSPRO) vs. 10% (placebo) (p<0.061); improved Forced
Vital Capacity (FVC) (p=0.029); Forced Expiratory Volume in 1 second (FEV1) (p=0.079) and
in the Neuropathic Visual Analogue Scale (VAS) (p=0.046). In addition,no treatment-related
serious adverse were recorded during the entire duration of the trial.
Professor Syed Haq, Daval’s Chief Medical & Scientific Director commented, “this is
the first time that AIMSPRO has appeared in an international peer-reviewed journal
focusing on a complex heterogenous connective tissue disorder and it is extremely
satisfying to witness that AIMSPRO is receiving this exposure,as a well-defined clinical
trial, by healthcare professionals and researchers in rheumatic diseases.”
Professor Denton was the principal investigator and Doctor Quillinan was the clinical
research fellow on the recently completed Double-Blind Placebo-Controlled Phase II
Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to
patients with Late Stage Established Diffuse Cutaneous Systemic Sclerosis (diffuse
scleroderma). They are both from the University College London Medical School, Centre for
Rheumatology and Connective Tissue Diseases at the Royal Free hospital in London.
Professor Haq, Jeffrey Vernes and Doctor McIntosh are with Daval International, who were
the sponsors of the trial.
To view the abstract of the publication, please click on this
The full publication is available for download for those with a subscription or it can
be viewed in the Annals of the Rheumatic Diseases journal, October 2013 edition and the
reference is Ann Rheum Dis doi:10.1136/annrheumdis-2013-203674
Notes to Editors
AIMSPRO(R) (HyperimmuneCaprine Sera, HICS) is a proprietary, purified,
protein-multi-peptide conjugate complex being developed as a novel, first-in-class
biological treatment for a number of immune diseases where regulation and stabilisation of
the immune system is required. It is believed that the drug has a unique mechanism of
action that supports its broad potential application in neuro-degenerative diseases.
AIMSPRO has been granted a Specials License by the UK’s MHRA and is also available in
Australia under Categories A and B of the TGA’s Special Access Scheme.
About Daval International Limited
DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the
development and delivery of novel and distinctive treatments for serious unmet medical
needs through a combination of innovation, dedication, entrepreneurship, skilled science
and partnership. From its inception in 2000, the founder and management team of Daval have
had a vision of bringing effective treatments that noticeably improve the quality of life
of patients suffering from the most serious debilitating neuro-degenerative, inflammatory
and autoimmune diseases and to offer a choice over and above some of the disease modifying
treatments available currently.
SOURCE Daval International